Tests shorter adaptive radiotherapy for cervical cancer patients
Compares a shorter adaptive radiation schedule with standard treatment in adults with cervical cancer.
Plain-language title generated from the registry record
Registry title: Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06641635, who can take part
Where in China
- Peking Union Medical College HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT06641635
- Record updated
- 3 November 2026
- Original description
The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.Read full original descriptionShow less
A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Study of Moderated Hypofractionated Online Adaptive Radiotherapy for Cervical Cancer
The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.
Inclusion: The patient is fully voluntary and has the capacity for autonomy, signing the informed consent form 30 days prior to enrollment; Age ≥18 and ≤75 years; FIGO 2018 stage IB1-IIB, IIIB cervical cancer; IIIC1 (lymph node metastasis ≤2 cm, without common iliac lymph node metastasis); Pathologically diagnosed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; Concurrent weekly cisplatin therapy ± immunotherapy; Able to undergo brachytherapy; ECOG performance status of 0-1, with an expected ability to tolerate lying flat for half an hour.
Exclusion: Patients who received other anticancer treatments, including chemotherapy, targeted therapy, or immunotherapy, before concurrent chemoradiotherapy; History of prior abdominal or pelvic radiotherapy; Patients who have undergone cervical cancer surgery; Patients with active infections or fever; Other severe diseases that may significantly affect clinical trial compliance, such as unstable heart disease, kidney disease, chronic hepatitis requiring treatment, poorly controlled diabetes, or mental disorders; FIGO stages IA, IIIA, IIIC2, IVA, or IVB; FIGO stage IIIC1 with lymph nodes >2 cm, or with common iliac lymph node metastasis; Pregnant or breastfeeding women.